Investors remain leery of the biotech industry

Oh, those fickle biotech investors. In Vivo says that biotech investors haven't proven to be very bullish about the money that pharma companies are pumping into emerging developers through new collaborations. To make its point, In Vivo highlights a series of big-dollar deals at public biotech companies and their subsequent drop in stock price.

To be fair, notes In Vivo, the equities market has been shaken up recently. But the good partnership news should have overcome the Wall Street jitters, insists the blog. It's all a sign that the market no longer cares about such market validations.

- read the analysis in In Vivo

Related Articles:
Pharma noshes at the biotech buffet. Report
VC adds billions in its pursuit of biotech ventures. Report
Billion-dollar baby: Biotech still on a roll with VC funds. Report
Biotech stocks surge as investors anticipate buyouts. Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.